Impurities test for Tranexamic Acid (EP method)

Applications |  | Thermo Fisher ScientificInstrumentation
HPLC
Industries
Pharma & Biopharma
Manufacturer
Thermo Fisher Scientific

Importance of the Topic


  • The control of impurities in pharmaceutical compounds is critical to ensure drug safety and efficacy.
  • Tranexamic acid is widely used as an antifibrinolytic agent, making reliable impurity testing essential for quality assurance.

Objectives and Study Overview


  • Present a validated European Pharmacopeia (EP) method for identifying and quantifying impurities in tranexamic acid.
  • Describe sample preparation, chromatographic conditions, and system suitability criteria.
  • Demonstrate method performance through resolution and relative retention time measurements.

Methodology and Instrumentation


  • Sample Preparation
    • Test solution: 0.2 g tranexamic acid dissolved in water and diluted to 20 mL.
    • Reference solution A: 5 mL test solution diluted to 100 mL, then 1 mL of that to 10 mL.
    • Reference solution B: 20 mg tranexamic acid impurity C in water to 2 mL.
    • Reference solution C: 12 mg impurity D to 100 mL, further dilutions to achieve final volume.
  • Chromatographic Conditions
    • Instrument: UltiMate 3000 LC.
    • Column: Hypersil GOLD, 4.6×250 mm, 5 μm.
    • Mobile phase: phosphate buffer with triethylamine and sodium lauryl sulfate, pH 2.5, mixed with methanol (60:40).
    • Mode: isocratic, flow rate 0.9 mL/min, column temperature 25 °C.
    • Detection: UV at 220 nm, injection volume 20 μL, run time 40 min.
  • System Suitability Criteria
    • Resolution between tranexamic acid and impurity C >= 1.5.
    • Relative retention times (RRT) for impurities compared to the main peak.

Main Results and Discussion


  • Resolution achieved between tranexamic acid and impurity C was 3.48, exceeding the EP requirement of 1.5.
  • Observed RRT values:
    • Impurity C: 1.15 (target ~1.1).
    • Impurity D: 1.22 (target ~1.3).
    • Impurity B: 1.54 (target ~1.5).
  • Chromatograms confirmed clear separation of all identified impurities within a 40 min runtime.
  • Method demonstrates high specificity, suitable for routine quality control.

Benefits and Practical Applications


  • Provides a robust assay for impurity profiling in tranexamic acid batches.
  • Supports regulatory compliance by meeting EP standards.
  • Enables laboratories to reliably monitor critical impurities in production and stability studies.

Future Trends and Applications


  • Integration with advanced detectors, such as mass spectrometry, for structural confirmation of unknown impurities.
  • Adoption of shorter columns and faster gradients to reduce analysis time.
  • Implementation of automated data processing and digital workflows for enhanced throughput.

Conclusion


  • The EP method for tranexamic acid impurity testing is validated, specific, and reliable for quality control laboratories.
  • System suitability results exceed required criteria, ensuring accurate detection and quantification of related substances.
  • The approach supports pharmaceutical manufacturers in maintaining product purity and safety.

References


  • No external references cited in this summary.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Impurities test for Mefenamic Acid (EP- method)
Impurities test for Mefenamic Acid (EP- method)
|Thermo Fisher Scientific|Applications
Impurities test for Cefradine (EP- method)
Impurities test for Cefradine (EP- method)
|Thermo Fisher Scientific|Applications
Impurities test for Cefalexin (EP-8.0 method)
Impurities test for Cefalexin (EP-8.0 method)
|Thermo Fisher Scientific|Applications
Determination of spectinomycin and related impurities in spectinomycin dihydrochloride